Navigation Links
Prospect Therapeutics' In Vitro Studies Demonstrate that GCS-100 Drug Binds to and Blocks the Effects of Galectin-3
Date:6/15/2009

WELLESLEY HILLS, Mass., June 15 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") announced today that in vitro studies have demonstrated that GCS-100 binds to and blocks the effects of galectin-3. Galectin-3 plays an important role in tumor cell survival, new blood vessel growth, cell proliferation and tumor metastasis, which is the spread of cancer beyond its primary site. As a result, this product candidate may have multiple benefits in combating cancer cells, including:

  • Induction of apoptosis

  • Inhibition of angiogenesis

  • Inhibition of cancer cell proliferation

  • Inhibition of metastasis

The intellectual property, regulatory dossier, fixed assets and clinical inventory of Prospect will be sold at auction on Monday, June 29, 2009 at 12:00 noon.

Persons interested in bidding must sign a Confidentiality Agreement ("CA") obtained from Finn's Office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package.

About Prospect Therapeutics, Inc.

Prospect's lead product candidate, GCS-100, is a carbohydrate molecule designed to inhibit the activity of galectin-3, a protein found in high concentration in a broad range of human cancers and whose over-expression is associated with poor prognosis in cancer patients.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignment for the Benefit of Creditors in the biotech field was Spherics, Inc. and ActivBiotics, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@earthlink.net or visit the website at www.finnwarnkegayton.com


'/>"/>
SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Incs. GCS-100 Molecule
2. Prospective Evaluation Finds High Levels of Satisfaction with ConvaTec Moldable Skin Barrier
3. Prospect Therapeutics, Inc.s GCS-100 Exhibits a Low Toxicity Profile in Cancer Patients
4. Americans United for Life Announces Legal Prospectus on Probable Supreme Court Nominees
5. Scientists Heartened at Prospect of End to Stem Cell Ban
6. Alliance Techs RFID Technology Enhances Carestream Healths Capability to Connect with Key Prospects at RSNA
7. Natural Healers Researches Natural Health Careers to Make the Prospective Holistic Health Students' Job Easier
8. Encouraging Prospects for Medical Imaging Equipment Services in Europe
9. U.S. Surrogacy Firm to Provide Private Consultations in the UK for Prospective Parents
10. Frozen Egg Bank Launches New Donor Web Site that Helps Prospective Parents Start a Family
11. Interleukin-12 indicates survival prospects for melanoma patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 2017 , ... Benefits delivery trailblazer, Hodges-Mace, LLC, ... benefits dashboard solving one of the top frustrations in employee benefits – how ... time, employees can access up-to-date information and account balances for all of their ...
(Date:3/23/2017)... ... March 23, 2017 , ... Michael Lanteri ... the greater Fort Collins area, has unveiled a collaboration with nonprofit Big Bones ... Donations to this worthy cause may now be made at http://bigbonescaninerescue.com/ . ...
(Date:3/23/2017)... ... 23, 2017 , ... ChenMed, a privately owned medical, management ... strategic executive team expansion needed to further optimize growth and performance. , “We ... Christopher Chen, MD, ChenMed Chief Executive Officer. “George Wheeler and Donald Trexler ...
(Date:3/23/2017)... ... 23, 2017 , ... Inflow IQ & Inflownomics of Raleigh, NC introduce a ... solid foundation. As experts in dangerous situations the Inflow IQ team can help ... deliver ripe, fresh, clean & refreshing knowledge systems that enhance life. , ...
(Date:3/23/2017)... Texas (PRWEB) , ... March 23, 2017 , ... ... Command (USSOCOM) awarded Task Force Dagger Foundation the US Special Operations Command’s Patriot ... During the presentation, General Thomas thanked Task Force Dagger Foundation for its significant ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)...  The goal of the pilot is to ... prescription drugs as they are distributed in ... from US FDA to better protect consumers by improving ... Blockchain startup Chronicled, which links the physical ... technology and recently raised $6.25M, and the LinkLab, a ...
(Date:3/23/2017)... INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") (CSE: ... AB Laboratories Inc. ("AB Labs") has successfully completed several ... Access to Cannabis for Medical Purposes Regulations ("ACMPR") located ... The facility, which was licensed for Cultivation under ... half capacity, with full production capacity scheduled by the ...
(Date:3/23/2017)... CRANBURY, N.J. , March 23, 2017 ... pharmaceutical company, announced a major milestone today.  ... meetings with the U.S. Food and Drug ... a clear clinical and regulatory path forward ... compound, CPI-613, in patients with acute myeloid ...
Breaking Medicine Technology: